课题基金 / 基金详情

Partial epigenetic reprogramming of retinal pigment cells in age-related degeneration, dysfunction, and injury

Partial epigenetic reprogramming of retinal pigment cells in age-related degeneration, dysfunction, and injury
视网膜色素细胞在年龄相关变性、功能障碍和损伤中的部分表观遗传重编程
批准号:
10644270
负责人:
Zhengping Hu
金额:
$11.4万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2025-06-30
关键词:
AdultAgeAge related macular degenerationAgingAtrophicBlindnessCell AgingCell DeathCell ReprogrammingCell physiologyCellsCellular MorphologyCellular StressCholesterolComplementComplement ActivationCrush InjuryDNADNA MethylationDataDepositionDevelopmentDietDoxycyclineDrynessElderlyElectrophysiology (science)ElectroretinographyEpigenetic ProcessExudative age-related macular degenerationEye diseasesFatty acid glycerol estersFunctional disorderGene DeliveryGene ModifiedGlaucomaHeterozygoteHumanIn VitroInjuryInvestigationKnowledgeMediatingMentorsModelingModificationMolecularMorphologyMusNeural RetinaNitrogenNonexudative age-related macular degenerationOptic NerveOxidative StressOxygenPathologicPathologyPathway interactionsPatientsPatternPhasePhotoreceptorsPlayPopulationProcessRegenerative capacityReportingResearch PersonnelResistanceRetinaRetinal DegenerationRetinal DiseasesRetinal Ganglion CellsRetinal PigmentsRiskRisk FactorsRoleSafetySerumSignal PathwaySiteStructure of retinal pigment epitheliumTestingTherapeuticTobaccoTobacco smoking behaviorTrainingTransmission Electron MicroscopyVisionWorkage relatedagedaxon regenerationbevacizumabcareercell injurycigarette smokingcomparativeepigenomeepithelial injuryhigh riskimprovedin vivoin vivo Modelin vivo regenerationinduced pluripotent stem cellinsightjuvenile animalmethylation patternmouse modelneovascularnovel therapeutic interventionoxidized low density lipoproteinpluripotencypreventprogramsresponsesenescenceskillssodium iodatestem cell differentiationtranscriptome

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Retinal pigment epithelial (RPE) cell dysfunction and damage are hallmarks of age-related macular degeneration (AMD), the leading cause of blindness in the elderly. While anti-VEGF has revolutionized the management of wet or exudative AMD, there is currently no treatment available for non-exudative AMD. Aging is the major risk factor for RPE degeneration and the development of AMD. During aging, epigenetic changes disrupt "youthful" DNA methylation patterns, leading to cellular dysfunction and senescence. Partial epigenetic reprogramming via ectopic induction of three Yamanaka factors, Oct4, Sox2, Klf4 (OSK), in retinal ganglion cells was recently reported to reprogram and reverse epigenetic age, leading to vision improvement in aged mice as well as in a mouse glaucoma model. I propose to test the hypothesis that partial epigenetic reprogramming can rescue age-related RPE cell degeneration and function in vivo, prevent RPE cell injury induced by a range of insults in vitro, and inhibit the formation of AMD-like pathologies in a mouse model with the following aims. (i) To determine whether OSK-mediated epigenetic reprogramming can restore RPE morphology and function in aged mice, I will examine the visual function and RPE morphology in aged mice with and without OSK induction by optomotor, ERG, RPE flatmount, and transmission electron microscopy. In addition, I will compare the transcriptomes and epigenomes of RPE from aged mice with and without OSK induction to assess the effect of OSK expression. (ii) To test the ability of OSK-induction in rescuing primary human RPE cells from morphologic and functional changes, as well as cell death following various AMD- associated insults in vitro, including oxidative stress, ox-LDL, and cigarette smoking extract. I will also examine the effect of OSK-induction in iPSC-RPE cells derived from high-risk and low-risk donors with AMD. (iii) Examine the role of OSK induction in NaIO3-treated mice, a short-term injury model that induces regional RPE atrophy, and in RPE specific aged Cfh heterozygous (Cfh+/-) mice fed with a high fat, high cholesterol diet, which have pathological changes mimicking early dry AMD. The results of these investigations will reveal the efficacy and viability of epigenetic reprogramming as a therapeutic strategy for RPE regeneration in vivo. My mentoring panel and the proposed training plan will equip me with new knowledge and skills to study age- related retinal diseases and will catalyze my transition to a career as an independent investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: